BPY2B
associated omics dataQ-omics provides the consensus-scored BPY2B profile across patient tissues and cancer cell-line models. BPY2B expression is associated with patient survival in 1 of 34 cancer types, with the highest sampling consensus in ESCA.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BPY2B — synthetic lethality, tumor antigen, and pembrolizumab response.
View premium →Survival associations
This table summarizes BPY2B survival associations across molecular data types. BPY2B RNA expression shows survival associations in the most cancer types (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BPY2B RNA expression–survival associations across cancer types. High BPY2B expression shows unfavorable associations in ESCA. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify ESCA as the clearest survival context for BPY2B RNA expression.
Cross-omics associations
This table shows molecular features associated with BPY2B in patient tissues and cancer cell lines. In cancer cell lines, BPY2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.